Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CIK Cells with Temozolomide for Malignant Gliomas
NCT02494804Phase 2Not yet recruiting
- Sponsor
- Changzhou First People's Hospital
- Start
- Jul 2015
- Primary completion
- Jul 2028
- Modality
- Allogeneic CAR-T, Tumor-Infiltrating Lymphocytes (TILs), TCR-Engineered T Cells
01
Overview
A Phase 2 trial of unmodified CIK in malignant glioma, sponsored by Changzhou First People's Hospital. Planned start Jul 2015; status: not yet recruiting.
02
Drugs
unmodified CIK
03
Conditions
malignant glioma
Beyond the preview
Go deeper on NCT02494804.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02494804.